UY32142A - Preparación de una quinoliniloxidifenilciclopropanodicarboxamida - Google Patents

Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Info

Publication number
UY32142A
UY32142A UY0001032142A UY32142A UY32142A UY 32142 A UY32142 A UY 32142A UY 0001032142 A UY0001032142 A UY 0001032142A UY 32142 A UY32142 A UY 32142A UY 32142 A UY32142 A UY 32142A
Authority
UY
Uruguay
Prior art keywords
preparation
quinoliniloxidifenilciclopropanodicarboxamida
compound
relates
present
Prior art date
Application number
UY0001032142A
Other languages
English (en)
Inventor
Zhou Xiaoming
Nicole Marie Deschamps
Michael Tolar Martin
Michael John Monteith
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of UY32142A publication Critical patent/UY32142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un compuesto de la fórmula III siguiente: en el que R1-R4 son como se define en la presente memoria. La presente invención también se refiere a la preparación de compuestos intermedios usados para preparar el compuesto de fórmula III:
UY0001032142A 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida UY32142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10045208P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
UY32142A true UY32142A (es) 2010-05-31

Family

ID=42058136

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032142A UY32142A (es) 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Country Status (8)

Country Link
US (1) US8314232B2 (es)
EP (1) EP2339918A4 (es)
JP (1) JP5587324B2 (es)
CN (1) CN102227164A (es)
AR (1) AR075084A1 (es)
TW (1) TW201035017A (es)
UY (1) UY32142A (es)
WO (1) WO2010036831A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293897B2 (en) 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CA2752421C (en) 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2563362B1 (en) * 2010-04-29 2014-03-12 Deciphera Pharmaceuticals, LLC Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 Ｃ-ｍｅｔ調節劑醫藥組合物
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
EP2768796B1 (en) * 2011-10-20 2019-11-20 Exelixis, Inc. Process for preparing quinoline derivatives
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN102977014B (zh) 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
BR112015023109A2 (pt) 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CA2939546C (en) 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112194622A (zh) * 2020-09-24 2021-01-08 上海毕得医药科技有限公司 一种5-氯喹啉-4-醇的合成方法
WO2024110606A1 (en) 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
EP1711495A2 (en) * 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer

Also Published As

Publication number Publication date
WO2010036831A1 (en) 2010-04-01
EP2339918A4 (en) 2012-06-06
US8314232B2 (en) 2012-11-20
TW201035017A (en) 2010-10-01
EP2339918A1 (en) 2011-07-06
JP2012503671A (ja) 2012-02-09
US20100081805A1 (en) 2010-04-01
JP5587324B2 (ja) 2014-09-10
CN102227164A (zh) 2011-10-26
AR075084A1 (es) 2011-03-09

Similar Documents

Publication Publication Date Title
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
IN2012DN02751A (es)
CU20110052A7 (es) Compuestos orgánicos
MX377930B (es) Proceso para fabricar compuestos de quinolona.
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
MX2019003738A (es) Compuestos antivirales.
ECSP10010434A (es) Inhibidores de hsp90
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20110286A (es) Proceso para la preparacion de derivados de l-alanina protegidos
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
CR20120592A (es) Intermedios de agomelatina y métodos de preparación de estos
CR20110208A (es) Proceso para la preparación de benzonorbornenos
CY1119697T1 (el) Μεθοδος παρασκευης ενωσεων α-γαλακτοζυλο κεραμιδιων
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
BR112012008952A2 (pt) microbicidas

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20101124